We have advised the CEO and management team of Synthon, a global pharmaceutical company focusing on generic drugs, on its sale by BC Partners to Goldman Sachs Alternatives (Goldman Sachs).
BC Partners and Goldman Sachs have entered into an agreement under which Goldman Sachs will acquire a majority stake in Synthon from funds advised by BC Partners. BC Partners will retain a minority stake in Synthon to support future growth.
We have advised Synthon's CEO and management team on both their sale and reinvestment arrangements with Goldman Sachs as the incoming investor.
The transaction is expected to complete in Q2 2025, subject to regulatory approvals.
Headquartered in the Netherlands, Synthon is a vertically integrated, global leader in the development and manufacturing of complex generics drugs. Synthon has a global footprint with direct presence in eight countries, including four R&D labs as well as four manufacturing sites located in Spain, Czech Republic, Argentina, and Chile.
Commenting on the transaction, private equity partner and Head of M&A, Emma Danks said: "It was great to have advised Synthon's management team on the sale by BC Partners to Goldman Sachs and the reinvestment. This deal demonstrates the primacy of our expertise in both private equity transactional work and the life sciences sector. It has been a pleasure working with Anish and his team as well as all parties involved, supporting Synthon's management team as they embark on this new chapter with Goldman Sachs. We look forward to seeing the continued evolution and success of all parties."
Suzy Davis, private equity partner comments: "There is a growing demand for increasingly complex generic drugs and this agreement will see Synthon capitalising further on the vast opportunities that the market has to offer. We are excited to have supported Anish and his team on this transformative transaction and we look forward to watching Synthon's continued growth in the future."
CEO of Synthon, Anish Mehta comments: "BC Partners have been an important strategic partner for Synthon in the last few years, and we are excited to be partnering with Goldman Sachs along with BC Partners as we look to the next phase of our growth. Thank you to the Taylor Wessing team for their incredible support and collaboration on this transaction. Their expertise in private equity transactional advice in competitive situations, combined with their in-depth knowledge of the life sciences sector, was critical in ensuring a successful outcome for all parties involved."
The deal was led by our UK Private Equity team with partners Emma Danks and Suzy Davis, senior associate Alexandra Poland, associate Kayla Sinclair, and trainee solicitors Miranda Robertson and Clover May. Other members of the team included partner James Ross and associate Sophia Hampton in the UK Tax and Incentives team, and partner Antony Jonkman in the Netherlands Corporate team.
